Carl M. Gay, MD, PhD

Peer-Reviewed Articles

1. Zhang B, Alder L, Rosner S, Desai A, Cooper AJ, Yimer H, Bogdanska W, Naqash AR, Taylor A, Joshi U, Carlisle J, Champiat S, Altan M, Vega MF, Halm J, Manzano JG, Fenton G, Nie Y, Wang K, Parma M, Rudin CM, Chiang A, Byers LA, Gay CM, Puri S. A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS. Lung Cancer 211:108870, 2026. e-Pub 2026. PMID: 41371100.
2. Tanimoto A, Ramkumar K, Stewart CA, Zhang B, Concannon K, Cardnell RJ, Shen L, Wang Q, Wang J, Gay CM, Byers LA. The impact of targeting TRAF2 and NCK-interacting protein kinase (TNIK) on anti-tumor effect and tumor immune environment in c-MYC-high small cell lung cancer. J Thorac Oncol, 2025. e-Pub 2025. PMID: 41456708.
3. Bose M, Ruoff C, Ehsan S, Stewart CA, Duarte A Jr, Bhattacharyya S, Li J, Benedict A, Welte T, Victorian A, Lujan FE, Diao L, Wang J, Chen K, Zhang B, Wang R, Soto LS, Serrano AG, Cardnell R, Gay CM, Byers LA, Karacosta LG. CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level. bioRxiv, 2025. e-Pub 2025. PMID: 41446220.
4. Boettiger K, Kovacs I, Horvath L, Ernhofer B, Schelch K, Pozonec MD, Teglas V, Aigner C, Megyesfalvi E, Renyi-Vamos F, Bogos K, Lang C, Deloria AJ, Gay CM, Byers LA, Sage J, Hirsch FR, Megyesfalvi Z, Dome B. Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments. Cancer Res, 2025. e-Pub 2025. PMID: 41411619.
5. Xie M, Vuko M, Saran S, Liu S, Chambers AG, Baakza H, Angell HK, Ng F, Gay CM, Cardnell RJ, Segerer FJ, Andoni A, Rodriguez-Canales J, Waring PM, Schick M, Barrett JC, Byers LA, Fabbri G. Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer. Mol Cancer 25(1):6, 2025. e-Pub 2025. PMID: 41331472.
6. Li H, Hong L, Rocha P, Bach R, Solis Soto LM, Rinsurongkawong W, Zhang B, Araujo HA, Elamin YY, Altan M, Arrechedera CA, Zhou J, Khan KB, Lu W, Young E, Gay CM, Cascone T, Byers LA, Skoulidis F, Blumenschein G, Fossella FV, Tsao A, Negrao MV, Vokes N, Wu J, Tran HT, Wistuba II, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Le X, Zhang J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers (Basel) 17(23), 2025. e-Pub 2025. PMID: 41375002.
7. Stewart CA, Ramkumar K, Wang R, Xi Y, Halliday A, Diao L, Wang Q, Serrano A, Groves S, Heeke S, Tanimoto A, Kaiser L, Lewis W, Bose M, Da Rocha P, Karacosta L, Quaranta V, Wang J, George J, Solis Soto LM, Zhang B, Heymach JV, Byers LA, Gay CM. YAP1 defines an emergent, plastic population of relapsed small cell lung cancer. bioRxiv, 2025. e-Pub 2025. PMID: 41279637.
8. Cooper AJ, Herzberg B, Parma M, Wang K, Alder L, Weber UM, Patil T, Joshi U, Puri S, Saqi A, Clark P, Gay CM, Cascone T, Singhi EK, Blumenschein G, Skoulidis F, Tu J, Stinchcombe TE, Rudin CM, Shu CA, Byers LA, Yu H, Zhang B. Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer. JCO Precis Oncol 9:e2500538, 2025. e-Pub 2025. PMID: 41166675.
9. Gay CM, Owonikoko TK, Byers LA, Choudhury NJ, Ahmed S, Cain Z, Qian X, Brentnall M, Heeke S, Poi M, Wu S, Rudin CM. Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular Subtypes. Clin Cancer Res 31(16):3476-3482, 2025. e-Pub 2025. PMID: 40553459.
10. Zhang B, Shah KB, Parma M, Wang K, Singhi EK, Lewis W, Rivera M, Altan M, Pozadzides J, Le X, Vokes N, Fossella F, O'Brien B, Wang C, Tom MC, Beckham T, Swanson T, Bronk J, Lin SH, Vega MF, Jacome J, Halliday A, Negrao M, Zhang J, Gibbons DL, Heymach JV, Byers LA, Gay CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report. J Thorac Oncol 20(8):1131-1138, 2025. e-Pub 2025. PMID: 40126456.
11. Heeke S, Gandhi S, Tran HT, Lam VK, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff MB, Le X, Tu J, Saad MB, Pek M, Poh J, Ngeow KC, Tsao A, Cascone T, Negrao MV, Wu J, Blumenschein GR Jr, Heymach JV, Elamin YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clin Res Rep 6(4):100795, 2025. e-Pub 2025. PMID: 40160974.
12. Morris BB, Heeke S, Xi Y, Diao L, Wang Q, Rocha P, Arriola E, Lee MC, Tyson DR, Concannon K, Ramkumar K, Stewart CA, Cardnell RJ, Wang R, Quaranta V, Wang J, Heymach JV, Nabet BY, Shames DS, Gay CM, Byers LA. DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer. Mol Cancer 24(1):90, 2025. e-Pub 2025. PMID: 40114214.
13. Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K. Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. J Thorac Oncol 20(3):383-394, 2025. e-Pub 2025. PMID: 39505259.
14. Serrano AG, Rocha P, Freitas Lima C, Stewart A, Zhang B, Diao L, Fujimoto J, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Concannon KF, Halperin DM, Bogdan C, Sircar K, Zhang M, Cargill K, Wang Q, Aparicio A, Lazar A, Hernandez S, Estrella J, Ramalingam P, El-Naggar A, Kalhor N, Gay CM, Byers LA, Solis Soto LM. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol 8(1):268, 2024. e-Pub 2024. PMID: 39558076.
15. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
16. Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Duarte A Jr, Sahu M, Novegil VY, Weissman BE, Frumovitz M, Kalhor N, Solis Soto L, da Rocha P, Vokes N, Gibbons DL, Wang J, Heymach JV, Glisson B, Byers LA, Gay CM. YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. Clin Cancer Res 30(20):4743-4754, 2024. e-Pub 2024. PMID: 39150543.
17. Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol:JCO2400533, 2024. e-Pub 2024. PMID: 39378386.
18. Jin Y, Wu Y, Reuben A, Zhu L, Gay CM, Wu Q, Zhou X, Mo H, Zheng Q, Ren J, Fang Z, Peng T, Wang N, Ma L, Fan Y, Song H, Zhang J, Chen M. Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer. Cell Discov 10(1):93, 2024. e-Pub 2024. PMID: 39231924.
19. Reck M, Nadal E, Girard N, Filippi AR, Martin LW, Gay CM, Petersen C, Gale D, Emeribe UA, Georgoulia N, Perez IED, Spicer JD. MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC. Clin Lung Cancer 25(6):587-593.e3, 2024. e-Pub 2024. PMID: 39003185.
20. Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O'Brien C, Paz-Ares L, Goldman JW, Garassino MC, Gay CM, Heymach JV, Jiang H, Barrett JC, Stewart RA, Lai Z, Byers LA, Rudin CM, Shrestha Y. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer 23(1):115, 2024. e-Pub 2024. PMID: 38811992.
21. Park S, Hong TH, Hwang S, Heeke S, Gay CM, Kim J, Jung HA, Sun JM, Ahn JS, Ahn MJ, Cho JH, Choi YS, Kim J, Shim YM, Kim HK, Byers LA, Heymach JV, Choi YL, Lee SH, Park K. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer. EBioMedicine 102:105062, 2024. e-Pub 2024. PMID: 38492534.
22. Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen QN, Liao Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol 193:110121, 2024. e-Pub 2024. PMID: 38311031.
23. Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, Gayevskiy V, Elhossiny AM, Srivastava MK, Patil NS, Smith KA, Jesudason R, Chan C, Chang PS, Fernandez M, Rost S, McGinnis LM, Koeppen H, Gay CM, Minna JD, Heymach JV, Chan JM, Rudin CM, Byers LA, Liu SV, Reck M, Shames DS. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell 42(3):429-443.e4, 2024. e-Pub 2024. PMID: 38366589.
24. Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horvath I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 42(2):225-237.e5, 2024. e-Pub 2024. PMID: 38278149.
25. Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep 5(2):100623, 2024. e-Pub 2024. PMID: 38357092.
26. Liu SV, Mok TSK, Nabet BY, Mansfield AS, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair MJ, Garassino MC, Gay CM, Heymach JV, Byers LA, Lam S, Cardona A, Morris S, Adler L, Shames DS, Reck M. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer 186:107418, 2023. e-Pub 2023. PMID: 37931445.
27. Megyesfalvi Z, Heeke S, Drapkin BJ, Solta A, Kovacs I, Boettiger K, Horvath L, Ernhofer B, Fillinger J, Renyi-Vamos F, Aigner C, Schelch K, Lang C, Marko-Varga G, Gay CM, Byers LA, Morris BB, Heymach JV, Van Loo P, Hirsch FR, Dome B. Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies. Cancer Cell 41(9):1535-1540, 2023. e-Pub 2023. PMID: 37699331.
28. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
29. Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, Wang Q, Shen L, Cardnell RJ, Wang J, Polanska UM, Andersen C, Saeh J, Pease JE, Travers J, Fabbri G, Gay CM, Urosevic J, Byers LA. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer. Clin Cancer Res 29(16):3237-3249, 2023. e-Pub 2023. PMID: 37289191.
30. Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep 4(8):100533, 2023. e-Pub 2023. PMID: 37649681.
31. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
32. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN Jr, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G Jr, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
33. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
34. Della Corte CM, Ciaramella V, Ramkumar K, Vicidomini G, Fiorelli A, Nardone V, Cappabianca S, Cozzolino I, Zito Marino F, Di Guida G, Wang Q, Cardnell R, Gay CM, Ciardiello D, Martinelli E, Troiani T, Martini G, Napolitano S, Wang J, Byers LA, Ciardiello F, Morgillo F. Triple Blockade of Ido-1, PD-L1 and MEK as a Potential Therapeutic Strategy in NSCLC. J Transl Med 20(1):541, 2022. e-Pub 2022. PMID: 36419183.
35. Tian Y, Li Q, Yang Z, Zhang S, Xu J, Wang Z, Bai H, Duan J, Zheng B, Li W, Cui Y, Wang X, Wan R, Fei K, Zhong J, Gao S, He J, Gay CM, Zhang J, Wang J, Tang F. Single-cell Transcriptomic Profiling Reveals the Tumor Heterogeneity of Small-cell Lung Cancer. Signal Transduct Target Ther 7(1):346, 2022. e-Pub 2022. PMID: 36195615.
36. Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic Expression of Schlafen 11 (SLFN11) in Circulating Tumour Cells as a Liquid Biomarker in Small Cell Lung Cancer. Br J Cancer 127(3):569-576, 2022. e-Pub 2022. PMID: 35440668.
37. Liu Y, Zhang Z, Rinsurongkawong W, Gay CM, Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, Swisher S, Gandhi S, Lee PP, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, Lin SH. Association of Driver Oncogene Variations with Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Netw Open 5(6):e2215589, 2022. e-Pub 2022. PMID: 35666500.
38. Della Corte CM, Fasano M, Ciaramella V, Cimmino F, Cardnell R, Gay CM, Ramkumar K, Diao L, Di Liello R, Viscardi G, Famiglietti V, Ciardiello D, Martini G, Napolitano S, Tuccillo C, Troiani T, Martinelli E, Wang J, Byers L, Morgillo F, Ciardiello F. Anti-tumor Activity of Cetuximab plus Avelumab in Non-small Cell Lung Cancer Patients Involves Innate Immunity Activation: Findings from the CAVE-Lung Trial. J Exp Clin Cancer Res 41(1):109, 2022. e-Pub 2022. PMID: 35346313.
39. Jin Y, Chen Y, Tang H, Hu X, Hubert SM, Li Q, Su D, Xu H, Fan Y, Yu X, Chen Q, Liu J, Hong W, Xu Y, Deng H, Zhu D, Li P, Gong Y, Xia X, Gay CM, Zhang J, Chen M. Activation of PI3K/AKT Pathway is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer. Clin Cancer Res 28(3):526-539, 2022. e-Pub 2022. PMID: 34921019.
40. Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and Heterogeneous T Cell Repertoire is Associated with Copy Number Aberrations and Loss of Immune Genes in Small-cell Lung Cancer. Nat Commun 12(1):6655, 2021. e-Pub 2021. PMID: 34789716.
41. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung Cancer Models Reveal SARS-CoV-2-induced EMT Contributes to COVID-19 Pathophysiology. J Thorac Oncol 16(11):1821-1839, 2021. e-Pub 2021. PMID: 34274504.
42. Kundu K, Cardnell RJ, Zhang B, Shen L, Stewart CA, Ramkumar K, Cargill KR, Wang J, Gay CM, Byers LA. SLFN11 Biomarker Status Predicts Response to Lurbinectedin as a Single Agent and in Combination with ATR Inhibition in Small Cell Lung Cancer. Transl Lung Cancer Res 10(11):4095-4105, 2021. e-Pub 2021. PMID: 35004241.
43. Cargill KR, Stewart CA, Park EM, Ramkumar K, Gay CM, Cardnell RJ, Wang Q, Diao L, Shen L, Fan YH, Chan WK, Lorenzi PL, Oliver TG, Wang J, Byers LA. Targeting MYC-enhanced Glycolysis for the Treatment of Small Cell Lung Cancer. Cancer Metab 9(1):33, 2021. e-Pub 2021. PMID: 34556188.
44. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific Differences in Tumor Mutational Burden, PD-L1 Expression, and Outcomes from Immunotherapy in Non-small Cell Lung Cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
45. Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, Owonikoko TK, Groen HJM, Gay CM, Fujimoto J, de Groot P, Dunbar M, Kang K, He L, Sehgal V, Glasgow J, Bach BA, Ellis PM. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clin Cancer Res 27(14):3884-3895, 2021. e-Pub 2021. PMID: 33947690.
46. Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, Byers LA. AXL Inhibition Induces DNA Damage and Replication Stress in Non-small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Mol Cancer Res 19(3):485-497, 2021. e-Pub 2021. PMID: 33172976.
47. Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities. Cancer Cell 39(20):S1535-S6108, 2021. e-Pub 2021. PMID: 33482121.
48. Zhou N, Bott M, Park BJ, Vallières E, Wilshire CL, Yasufuku K, Spicer JD, Jones DR, Sepesi B, Working Group SCLC. Predictors of Survival following Surgical Resection of Limited-stage Small Cell Lung Cancer. J Thorac Cardiovasc Surg, 2021. e-Pub 2021. PMID: 33349449.
49. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and Survival after Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol 16(2):269-277, 2021. e-Pub 2021. PMID: 33198942.
50. Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist, 2020. e-Pub 2020. PMID: 32608142.
51. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
52. Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING Pathway Expression Identifies Non-small Cell Lung Cancers with an Immune-responsive Phenotype. J Thorac Oncol 15(5):777-791, 2020. e-Pub 2020. PMID: 32068166.
53. Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell Analyses Reveal Increased Intratumoral Heterogeneity after the Onset of Therapeutic Resistance in Small-cell Lung Cancer. Nature Cancer 1:423-436, 2020. e-Pub 2020. PMID: 33521652.
54. Wang Y, Zheng Q, Jia B, An T, Zhao J, Wu M, Zhuo M, Li J, Zhong J, Chen H, Yang X, Chi Y, Dong Z, Sepesi B, Zhang J, Gay CM, Wang Z. Effects of Surgery on Survival of Early-Stage Patients with SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. Front Oncol 10:626, 2020. e-Pub 2020. PMID: 32391280.
55. Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, Wang J, Byers LA. Combination Treatment of the Oral CHK1 Inhibitor, SRA737 and Low Dose Gemcitabine, Enhances the Effect of PD-L1 Blockade by Modulating the Immune Microenvironment in Small Cell Lung Cancer. J Thorac Oncol 14(12):2152-2163, 2019. e-Pub 2019. PMID: 31470128.
56. Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA. Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clin Cancer Res 25(1):346-357, 2019. e-Pub 2019. PMID: 30257981.
57. Carretero-Ortega J, Chhangawala Z, Hunt S, Narvaez C, Menendez-Gonzalez J, Gay CM, Zygmunt T, Li X, Torres-Vasquez J. GIPC Proteins Negative Modulate Plexind1 Signaling during Vascular Development. Elife 3(8), 2019. e-Pub 2019.
58. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, Network TR, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov 8(12):1548-1565, 2018. e-Pub 2018. PMID: 30322867.
59. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8(9):1156-1175, 2018. e-Pub 2018. PMID: 30012853.
60. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Research Network CGA, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23(1):194-212.e6, 2018. e-Pub 2018. PMID: 29617660.
61. Abeshouse A, Adebamowo C, Gay CM, et al. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171(4):950-965, 2017. e-Pub 2017. PMID: 29100075.
62. Stewart AC, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA. Dynamic Variations in Epithelial-to-mesenchymal Transition (EMT), ATM, and SLFN11 Govern Response to PARP Inhibitors and Cisplatin in Small Cell Lung Cancer. Oncotarget 8(17):28575-28587, 2017. e-Pub 2017. PMID: 28212573.
63. Gay CM, de Groot PM, Pietanza CM, Byers LA. Durable, Exceptional Response to Temozolomide in a Patient with Extensive-stage Small Cell Lung Cancer (ES-SCLC) Metastatic to Brain. Cancer Treat Commun 10:17-20, 2017. e-Pub 2017.
64. Gay CM, William WN, Wang SA, Oo TH. Thymoma Complicated by Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia. J Natl Compr Canc Netw 12(11):1505-9, 2014. e-Pub 2014. PMID: 25361796.
65. Zygmunt T, Gay CM, Blondelle J, Singh MK, Flaherty KM, Means PC, Herwig L, Krudewig A, Belting HG, Affolter M, Epstein JA, Torres-Vazquez J. Semaphorin-PlexinD1 Signaling Limits Angiogenic Potential via the VEGF Decoy Receptor sFlt1. Dev Cell 21(2):301-314, 2011. e-Pub 2011. PMID: 21802375.

Invited Articles

1. Zhang B, Ramkumar K, Cardnell RJ, Gay CM, Stewart CA, Wang WL, Fujimoto J, Wistuba II, Byers LA. A Wake-up Call for Cancer DNA Damage: The Role of Schlafen 11 (SLFN11) across Multiple Cancers. Br J Cancer 125(10):1333-1340, 2021. e-Pub 2021. PMID: 34294893.
2. Cargill KR, Hasken WL, Gay CM, Byers LA. Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers. Front Oncol 11:757323, 2021. e-Pub 2021. PMID: 34745994.
3. Singhi EK, Gay CM. Narrative Review of the Emerging Role of Molecular Biomarkers in Guiding the Definitive Management of Unresectable Non-small Cell Lung Cancer. Transl Lung Cancer Res 9(5):2051-2058, 2020. e-Pub 2020. PMID: 33209625.
4. Gay CM, Byers LA. PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?. J Thorac Oncol 14(8):1323-1326, 2019. e-Pub 2019. PMID: 31345330.
5. Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA. PARP Inhibitors: Extending Benefit beyond BRCA-Mutant Cancers. Clin Cancer Res 25(13):3759-3771, 2019. e-Pub 2019. PMID: 30760478.
6. Della Corte CM, Gay CM, Byers LA. Beyond Chemotherapy: Emerging Biomarkers and Therapies as Small Cell Lung Cancer enters the Immune Checkpoint Era. Cancer 125(4):496-498, 2019. e-Pub 2019. PMID: 30620399.
7. Sen T, Gay CM, Byers LA. Targeting DNA Damage Repair in Small Cell Lung Cancer and the Biomarker Landscape. Transl Lung Cancer Res 7(1):50-68, 2018. e-Pub 2018. PMID: 29535912.
8. Gay CM, Balaji K, Byers LA. Giving AXL the Axe: Targeting AXL in Human Malignancy. Br J Cancer 116(4):415-423, 2017. e-Pub 2017. PMID: 28072762.
9. Gay CM, Zygmunt T, Torres-Vazquez J. Diverse Functions for the Semaphorin Receptor PlexinD1 in Development and Disease. Dev Biol 349(1):1-19, 2011. e-Pub 2011. PMID: 36392104.

Review Articles

1. Qin K, Gay CM, Byers LA, Zhang J. The current and emerging immunotherapy paradigm in small-cell lung cancer. Nat Cancer 6(6):954-966, 2025. e-Pub 2025. PMID: 40473974.
2. Xia Y, Wang K, Zhao J, Arter Z, Zhang Y, Zhou J, Lu Y, Zeng L, Du R, Owens JA, Elamin YY, Gay CM, Skoulidis F, Tsao AS, Lu C, Cascone T, Gibbons DL, Zhang J, Chen O, Mok KKS, Nagasaka M, Li W, Heymach JV, Ou SI, Li M, Le X. Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review. J Thorac Oncol 20(4):465-474, 2025. e-Pub 2025. PMID: 39622411.
3. Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, Bunn PA Jr, Renyi-Vamos F, Schelch K, Prosch H, Byers LA, Hirsch FR, Dome B. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin 73(6):620-652, 2023. e-Pub 2023. PMID: 37329269.
4. Concannon K, Morris BB, Gay CM, Byers LA. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Mol Cell 83(5):660-680, 2023. e-Pub 2023. PMID: 36669489.

Professional Educational Materials

1. . Small Cell Lung Cancer. University of Texas MD Anderson Cancer Center Clinical Practice Algorithm, 2023.

Other Articles

1. Jin Y, Wu Y, Reuben A, Zhu L, Gay CM, Wu Q, Zhou X, Mo H, Zheng Q, Ren J, Fang Z, Peng T, Wang N, Ma L, Fan Y, Song H, Zhang J, Chen M Author Correction: Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer. Cell Discov 10(1):126, 2024. PMID: 39702462.
2. Wu Y, Verma V, Gay CM, Chen Y, Liang F, Lin Q, Wang J, Zhang W, Hui Z, Zhao M, Wang J, Chang JY Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis. Cancer 129(13):1969-1985, 2023. PMID: 36994945.

Editorials

1. Zhang B, Gay CM. Sacituzumab govitecan: another emerging treatment option for patients with relapsed small cell lung cancer. Transl Lung Cancer Res 14(9):4165-4169, 2025. PMID: 41132950.
2. Antonoff MB, Gay CM. Timing of local consolidative pulmonary resection for oncogene-driven stage IV lung cancer. J Thorac Cardiovasc Surg 170(3):876-881.e1, 2025. PMID: 40187554.
3. Gay CM, Parseghian CM, Byers LA. This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones. Cancer Cell 37(1):5-7, 2020. PMID: 31951562.
4. Della Corte CM, Gay CM, Byers LA, Morgillo F. ILK and SHP2 Expression Identify a Poor Prognostic Cohort of EGFR-mutant Lung Cancer. EBioMedicine 39:5-6, 2019. PMID: 30553753.

Abstracts

1. Stewart CA, Ramkumar K, Wang R, Yang Y, Zhang B, Xi Y, Diao L, Wang Q, Duarte A, Li P, Tanimoto A, Serrano AG, Vykoukal J, Bose M, Karacosta LG, Solis Soto L, Hanash S, Wang J, Heymach JV, Byers LA, Gay CM. Combination surface targeting strategies in relapsed small cell lung cancer (SCLC) to overcome intratumoral heterogeneity associated with treatment resistance. AACR Annual Meeting 2025 85(8 Supplement 1):2928, 2025. e-Pub 2025.
2. Concannon K, Morris B, Diao L, Sahu M, Lewis W, Sun X, Heeke S, Zhang B, Tran H, Hong L, Rinsurongkawong W, Nguyen M, Qin K, Li H, Zhang J, Lee J, Wang J, Cardnell R, Gay CM, Heymach J, Byers L. Smoking burden is associated with immunotherapy resistance in extensive stage small cell lung cancer. AACR Annual Meeting 2025 85(8 Supplement 1):3279, 2025. e-Pub 2025.
3. Ramkumar K, Stewart CA, Yang Y, Zhang B, Wang Q, Xi Y, Wang R, Serrano AG, Solis Soto LM, Wang J, Heymach JV, Gay CM, Byers LA. AXL-directed surface targeting approaches in recalcitrant pulmonary high-grade neuroendocrine carcinomas. AACR Annual Meeting 2025 85(8 Supplement 1):2931, 2025. e-Pub 2025.
4. Morris BB, Zhang Z, Lynch AR, Heeke S, Concannon K, Stewart CA, Wang R, Halliday A, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Zhang J, Gibbons DL, Vaporciyan AA, Gay CM, Tran HT, Heymach JV, Byers LA, Van Loo P. Reconstructing small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA. AACR Annual Meeting 2025 85(8 Supplement 1):1263, 2025. e-Pub 2025.
5. Heeke S, Valiev I, Kleimenov M, Sobol A, Barykin EP, Slizen MV, Evdokimova AO, Kushnarev V, Kosmin AV, Butusova AA, Clayton P, Paradiso F, Yong S, Bagaev A, Byers L, Heymach J, Gay CM. A novel machine learning classifier for SCLC transcriptional subtypes. AACR Annual Meeting 2025 85(8 Supplement 1):1101, 2025. e-Pub 2025.
6. Chen H, Zhang B, Serrano A, Hernandez S, Lu W, Trevino S, Vokes N, Liu X, Tian Y, Zhu B, Nilsson MB, Heymach JV, Zhang J, Solis Soto L, Gay CM, Byers LA, Le X. Spatially resolved protein profiling of tumor and immune microenvironment in EGFR mutant NSCLC with transformation to SCLC. AACR Annual Meeting 2025 85(8 Supplement 1):7166, 2025. e-Pub 2025.
7. Gay CM, Owonikoko TK, Byers LA, Choudhury NJ, Ahmed S, Cain Z, Qian X, Brentnall M, Heeke S, Poi M, Wu S, Rudin CM. Multidimensional analysis of B7 homolog 3 (B7-H3) RNA expression in small-cell lung cancer (SCLC) molecular subtypes, 2024 ASCO Annual Meeting. 2024 ASCO Annual Meeting 42(16 S), 2024. e-Pub 2024.
8. Zhen DB, Moseley A, Chiorean EG, Burgess EF, Swisher EM, Gay CM, Byers LA, Wistuba II, Mahdi H, Starr JS, Othus M, Chae YK, Kurzrock R. SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC), 2024 ASCO Annual Meeting. 2024 ASCO Annual Meeting 42(16 S), 2024. e-Pub 2024.
9. Zhang B, Ibrahim A, Stewart C, Diao L, Wang Q, Shen L, xi Y, Serrano A, Solis LM, Wang W, Ramkumar K, Cardnell RJ, Wang R, Duarte A, Wang J, Byers LA, Gay CM. Abstract 6392: Activity of HER2-and TROP2- antibody drug conjugates (ADCs) in small cell lung cancer (SCLC) models with SLFN11 as a predictive biomarker. 2024 AACR Annual Meeting, 2024. e-Pub 2024.
10. Concannon K, Sahu M, Lewis W, Tran H, Diao L, Xi Y, Morris B, Heeke S, Tang X, Stewart J, Valiev I, Raso G, Wang J, Sasaki K, Gay CM, Heymach JV, Byers LA. Abstract 5061: Improved survival and unique mutational signatures in small cell lung cancer arising in patients with limited tobacco use. 2024 AACR Annual Meeting, 2024. e-Pub 2024.
11. Tanimoto A, Ramkumar K, Stewart A, Zhang B, Cardnell R, Li S, Wang Q, Wang J, Gay CM, Byers LA. Abstract 6799: The impact of targeting TRAF2 and NCK-interacting protein kinase on anti-tumor effect and tumor immune environment in cMYC-high small cell lung cancer. 2024 AACR Annual Meeting, 2024. e-Pub 2024.
12. Stewart C, Groves SM, Wang R, Ramkumar K, Xi Y, Diao L, Serrano AG, Tanimoto A, Victorian AM, Bhattacharyya S, Halliday AJ, Kalhor N, Soto LM, Da Rocha PF, Vokes N, Karacosta LG, Wang J, Heymach JV, Quaranta V, Glisson B, Byers LA, Gay CM. Abstract 5864: YAP1 defines a highly plastic, persister cell population in small cell lung cancer (SCLC) following relapse. 2024 AACR Annual Meeting, 2024. e-Pub 2024.
13. Morris BB, Zhang Z, Heeke S, Concannon K, Zhang B, Rinsurongkawong W, Rinsurongkawong V, Lee J, Zhang J, Gibbons DL, Vaporciyan AA, Gay CM, Tran HT, Heymach JV, Byers LA, Loo PV. Abstract A022: Dissecting patterns of small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA. 2024 AACR Annual Meeting, 2024. e-Pub 2024.
14. Savin O, Netanely D, Heeke S, Gay CM, Estecio MR, Danan S, Zaouch S, Shuali A, Ehrich M, Byers LA, Heymach JV, Wasserstrom A, Frumkin D. Abstract 1722: Subtype classification of small cell lung cancer (SCLC) tissues using the EpiCheck methylation sensitive restriction-based PCR platform. 2024 AACR Annual Meeting, 2024. e-Pub 2024.
15. Paz-Ares LG, Gay CM, Zhou C, Kato T, Corrales L, Redhead K, Rahman A, Bradley D, Theogaraj E, Hutchinson KE, Shagan SM, Solomon BJ. A Phase I-III Platform Study Evaluating the Safety and Efficacy of Multiple Therapies in Patients with Biomarker-defined Locally Advanced, Unresectable Stage III Non–small-cell Lung Cancer (NSCLC). 2023 ASCO Annual Meeting 41(S16), 2023. e-Pub 2023.
16. Heeke S, Gandhi S, Tran HT, Lam VK, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff M, Le X, Tu JC, Pek M, Poh J, Ngeow KC, Tsao AS, Cascone T, Negrao MV, Blumenschein GR, Heymach J, Elamin YY. Longitudinal Tracking of ALK-positive Lung Cancer from Plasma using Circulating-tumor RNA and Circulating-tumor DNA in the BRIGHTSTAR Clinical Trial. 2023 ASCO Annual Meeting 41(S16), 2023. e-Pub 2023.
17. Abdel Karim NF, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao Y, Redman MW, Carrizosa DR, Wang W, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K. SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC). 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
18. Wang K, Fossella FV, Negrao MV, Cascone T, Gay CM, Le X, Vokes NI, Hume CB, Hassan AA, Gibbons DL, Lee JJ, Heymach J, Zhang J. Clinical Outcomes of Chemotherapy Rechallenge in Patients with Metastatic Non-small Cell Lung (NSCLC) who Progressed on Immunotherapy Maintenance after Front Line Platinum Doublets and Immunotherapy. 2023 ASCO Annual Meeting 41(S16), 2023. e-Pub 2023.
19. Heeke S, Gay CM, Estecio MR, Tran HT, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Arriola E, Hofman P, Kopparapu P, Lovly CM, Concannon K, Xi Y, Diao L, Wang Q, Wang J, Byers LA, Heymach J. Analysis of Tumor- and Circulating-free DNA Methylation to Identify Clinically Relevant Small Cell Lung Cancer Subtypes. 2023 ASCO Annual Meeting 41(S16), 2023. e-Pub 2023.
20. Morris BB, Nabet B, Shames D, Heeke S, Gay CM, Wang J, Zhang J, Heymach JV, Byers LA. Abstract 6115: Comprehensive DNA repair landscape analysis reveals novel small cell lung cancer biology. 2023 AACR Annual Meeting, 2023. e-Pub 2023.
21. Ramkumar K, Stewart CA, Tanimoto A, Wang Q, Xi Y, Morris BB, Wang R, Shen R, Cardnell RJ, Wang J, Gay CM, Byers LA. Combined inhibition of AXL and ATR enhances replication stress, cell death and immune response in small cell lung cancer. 2023 AACR Annual Meeting, 2023. e-Pub 2023.
22. Concannon K, Heeke S, Sahu M, Tang X, Sasaki K, Patel S, Raso MG, Tran H, Gay CM, Byers L. Abstract 1398: Clinical and transcriptomic analysis demonstrates improved survival and unique gene expression signatures among SCLC arising in patients with minimal tobacco use. 2023 AACR Annual Meeting, 2023. e-Pub 2023.
23. Hong L, Aminu M, Lu X, Saad MB, Chen P, Rinsurongkawong W, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Lee J, Roy-Chowdhuri S, Routbort MJ, Heymach JV, Wu J, Zhang J, Vokes NI. Abstract 964: Genomic and clinical predictors of early disease progression and chemoimmunotherapy benefit in advanced NSCLC. 2023 AACR Annual Meeting, 2023. e-Pub 2023.
24. Tanimoto A, Cardnell RJ, Morris BB, Ramkumar K, Li S, Wang Q, Stewart AC, Gay CM, Wang J, Byers LA. Abstract 3854: TNIK inhibition as a novel therapeutic in cMyc high/TTF1 low SCLC. 2023 AACR Annual Meeting, 2023. e-Pub 2023.
25. Zhang B, Yang Y, Stewart CA, Ramkumar K, Wang R, Cardnell RJ, Diao L, Wang Q, Wang J, Byers LA, Gay CM, Heymach JV. Subtype-specific targeting of cell surfaceome with CAR T therapies in small cell lung cancer. 2023 AACR Annual Meeting, 2023. e-Pub 2023.
26. Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Tanimoto A, Novegil VY, Solis Soto LM, Simoes da Rocha PF, Vokes N, Gibbons DL, Frumovitz M, Fujimoto J, Wang J, Glisson B, Byers LA, Gay CM. YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1, EMT and therapeutic vulnerability to MEK1 and CDK4/6 inhibition. 2023 AACR Annual Meeting, 2023. e-Pub 2023.
27. Gay CM, Stewart CA, Frumovitz M, Fujimoto J, Xi Y, Wang Q, Wang R, Novegil V, Altan M, Cascone T, Dasari A, Elamin YY, Fossella FV, Glisson BS, Lu CS, Negrao MV, Skoulidis F, Vokes N, Cardnell RJ, Wistuba II, Wang J, Heymach JV, Byers LA. A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas. 2023 AACR Annual Meeting, 2023. e-Pub 2023.
28. Zhen DB, Mayerson E, Chiorean EG, Burgess EF, Swisher EM, Gay CM, Byers LA, Wistuba II, Mahdi H, Das S, Starr JS, Othus M, Chae YK, Kurzrock R. SWOG S2012: Randomized Phase II/III Trial of First Line Platinum/etoposide (P/E) with or without Atezolizumab in Patients (pts) with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC). 2022 ASCO Annual Meeting 40(S16), 2022. e-Pub 2022.
29. Elamin YY, Negrao MV, Fossella FV, Byers LA, Zhang J, Gay CM, Tu JC, Pozadzides JV, Tran HT, Lu C, Feng L, Spelman AR, Blumenschein GR, Tsao AS, Heymach J. Results of a Phase 1b Study of Osimertinib Plus Sapanisertib or Alisertib for Osimertinib-resistant, EGFR-mutant Non–small Cell Lung Cancer (NSCLC). 2022 ASCO Annual Meeting 40(S16), 2022. e-Pub 2022.
30. Stewart CA, Xi Y, Wang R, Frumovitz MM, Wang J, Byers LA, Gay CM. Defining the Transcriptional Complexity of Persister Cell Populations in Relapsed Small Cell Lung Cancer Patient Biopsies. 2022 AACR Annual Meeting, 2022. e-Pub 2022.
31. Heeke S, Gay CM, Estecio MR, Stewart CA, Tran H, Zhang B, Tang X, Raso G, Concannon K, Guimaraes De Sousa L, Lewis WE, Nilsson M, Xi Y, Diao L, Wang Q, Zhang J, Wang J, Wistuba II, Byers LA, Heymach JV. Use of DNA methylation from tumor and plasma to identify four major small cell lung cancer subtypes with distinct biology and therapeutic vulnerabilities. 2022 AACR Annual Meeting, 2022. e-Pub 2022.
32. Xie M, Chugh P, Broadhurst H, Lai Z, Whitson D, Paz-Ares L, Gay CM, Byers LA, Rudin CM, Stewart R, Barrett JC, Shrestha Y. Durvalumab (D) + platinum-etoposide (EP) in 1L Extensive-stage Small-cell Lung Cancer (ES-SCLC): Exploratory Analysis of SCLC Molecular Subtypes in CASPIAN. 2022 AACR Annual Meeting, 2022. e-Pub 2022.
33. Lima CF, Rocha PS, Fujimoto J, Stewart CA, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Gay CM, Kalhor N, Byers LA, Solis-Soto LM. Delta-like Ligand 3 Immunohistochemical Expression Landscape in High-grade Lung Neuroendocrine Tumors. 2022 AACR Annual Meeting, 2022. e-Pub 2022.
34. Ramkumar K, Tanimoto A, Stewart CA, Wang Q, Shen L, Cardnell RJ, Rodriguez L, Gibbons DL, Wang J, Gay CM, Byers LA. Combined Inhibition of AXL and ATR Enhances Cell Death and Immune Response in Small Cell Lung Cancer. 2022 AACR Annual Meeting, 2022. e-Pub 2022.
35. Liu SV, Mok TSK, Mansfield AS, De Boer R, Losonczy G, Sugawara S, Krzakowski M, Smolin A, Hochmair M, Garassino MC, Gay CM, Heymach JV, Byers LA, McCleland M, Nabet BY, Morris S, Adler L, Shames DS, Reck M. IMpower133: Gene Expression Analysis in Long-term Survivors with ES-SCLC Treated with First-line Carboplatin and Etoposide +/- Atezolizumab. 2021 ESMO Annual Meeting, 2021. e-Pub 2021.
36. Cargill KR, Gay CM, Cardnell RJ, Fan Y, Wang Q, Diao L, Wang J, Byers LA. Comprehensive Metabolic Profiling and Vulnerabilities to Metabolic Inhibitors among Small Cell Lung Cancer Subtypes. 2020 AACR Annual Meeting, 2020. e-Pub 2020.
37. Della Corte CM, Ajpacaja L, Cardnell RJ, Gay CM, Wang Q, Shen L, Ramkumar K, Stewart AC, Fan YH, Adelman CA, Travers J, Wang J, Heymach J, Byers LA. Abstract 1749P: Activity of the Novel Aurora Kinase B inhibitor AZD2811 in Biomarker-defined Models of Small Cell Lung Cancer. 2019 ESMO Annual Meeting 30(Supp 5), 2019. e-Pub 2019.
38. Gay C, Diao L, Stewart C, Xi Y, Cardnell R, Swisher S, Roth J, Glisson B, Wang J, Heymach J, Byers LA. ASCL1, NEUROD1, and POU2F3 Drive Distinct Subtypes of Small Cell Lung Cancer with Unique Therapeutic Vulnerabilities. 2019 IASLC World Conference on Lung Cancer, 2019. e-Pub 2019.
39. Gay CM, Diao L, Stewart CA, Xi Y, Cardnell RJ, Swisher SG, Roth JA, Glisson BS, Wang J, Heymach JV, Byers LA. Abstract 3772: Inter- and Intra-tumoral Variations in ASCL1, NEUROD1, and POU2F3 Transcriptional Programs Underlie Three Distinct Molecular Subtypes of Small Cell Lung Cancers - Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. 2019 AACR Annual Meeting 79(Supp 13), 2019. e-Pub 2019.
40. Byers LA, Stewart A, Gay CM, Heymach J, Fernandez L, Lu D, Rich R, Chu L, Wang Y, Dittamore R. Abstract 2215: SLFN11 and EZH2 Protein Expression and Localization in Circulating Tumor Cells to Predict Response or Resistance to DNA Damaging Therapies in Small Cell Lung Cancer - Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. 2019 AACR Annual Meeting 79(Supp 13), 2019. e-Pub 2019.
41. Stewart CA, Gay CM, Xi Y, Fujimoto J, Kalhor N, Hartsfield PM, Tran H, Fernandez L, Lu D, Wang Y, Dittamore R, Zhang J, Swisher SG, Roth JA, Oliver TG, Heymach JV, Wistuba II, Glisson BS, Robson P, Wang J, Byers LA. Abstract 2899: Single-cell Analyses Reveal Increasing Intratumoral Heterogeneity as an Essential Component of Treatment Resistance in Small Cell Lung Cancer - Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. 2019 AACR Annual Meeting 79(Supp 13), 2019. e-Pub 2019.
42. Stewart CA, Gay CM, Xi Y, Siva V, Fujimoto J, Tong P, Diao L, Li L, Bolisetty M, Kalhor N, Lawson P, Vasquez M, Tran H, Wistuba II, Glisson B, Zhang J, Swisher SG, Roth JA, Heymach JV, Robson P, Wang J, Byers LA. Abstract 990: Single-cell Profiling of Small Cell Lung Cancer Circulating Tumor Cell-derived Xenograft Models Reveals Intratumoral Heterogeneity among Mediators of Chemoresistance - Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. 2018 AACR Annual Meeting 78(Supp 13), 2018. e-Pub 2018.
43. Gay CM, Tong P, Li L, Stewart CA, Sen T, Glisson BS, Heymach JV, Wang J, Byers LA. Abstract 2822: ATR Inhibitors are Active as Single Agents and in Combination with PARP1 and ATM Inhibitors in Molecularly Distinct Subsets of Small Cell Lung Cancer Models - Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. 2018 AACR Annual Meeting 78(Supp 13), 2018. e-Pub 2018.
44. Sen T, Chen L, Rodriguez BL, Gay CM, Li L, Li Y, Fan Y, Glisson B, Wang J, Piwnica-Worms H, Sage J, Heymach JV, Gibbons DL, Byers LA. Abstract A108: DNA Damage Repair Targeting Upregulates PD-L1 Level and Potentiates the Effect of PD-L1 Blockade in Small Cell Lung Cancer - AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA. 2017 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 17(Supp 1), 2018. e-Pub 2018.
45. Gay CM, Tong P, Cardnell RJ, Su X, Kalu NN, Banerjee U, Bara RO, Johnson FM, Heymach JV, Wang J, Byers LA. Abstract 1560: Differential Sensitivity Analysis for Resistant Malignancies (DISARM), A Novel Approach for Drug Screen Analysis, Identifies Common Candidate Drugs Across Platinum-resistant Cancer Types - Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. 2017 AACR Annual Meeting 77(Supp 13), 2017. e-Pub 2017.
46. Gay CM, Kundu S, Diao L, Glisson BS, Wang J, Heymach JV, Byers LA, Gibbons DL. Abstract LB-170 Unique MicroRNA Signatures in Small Cell Lung Cancer Correlate with Distinct Protein Expression Profiles and Drug Response - Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. 2016 AACR Annual Meeting 79(Supp 14), 2016. e-Pub 2016.
47. Ramkumar K, Stewart CA, Li P, Wang R, Ibrahim AH, Diao L, Shen L, Xi Y, Heeke S, Wang J, Zhang B, Byers LA, Gay CM. HER2- and TROP2-Directed Antibody Drug Conjugates Show Potent Antitumor Activities in Small Cell Lung Cancer. IASLC 2025 WCLC Annual Meeting.
48. Gay CM, Bagley SJ, Binder ZA, Fraietta JA, Desai AS, Nabavizadeh A, Marshall A, Leskowitz RM, Gonzalez VE, Gladney W, Barrett D, Silverbush D, Freeburg N, Chafamo D, Konanur G, Nasrallah M, Hwang WT, Siegel DL, June CH, Hexner EO, O'Rourke D. A phase 1 study of intracerebroventricular (ICV) delivery of bivalent chimeric antigen receptor (CAR) T-cells targeting EGFR and IL13Ra2 in patients with recurrent glioblastoma (rGBM). 2025 ASCO Annual Meeting.
49. Gonugunta A, Pan K, Gay CM, Singhi EK. Enhancing competence and confidence in thoracic oncology: A pilot study on the impact of self-assessment and reflection tools for hematology-oncology fellows. 2025 ASCO Annual Meeting.
50. Gonugunta A, Pan K, Gay CM, Singhi E. Enhancing competence and confidence in thoracic oncology: A pilot study on the impact of self-assessment and reflection tools for hematology-oncology fellows. 2025 ASCO Annual Meeting.
51. Zhang JJ, Zhu B, Salehjahromi M, Heeke S, Godoy M, Negrao MV, Vokes N, Le X, Pozadzides JV, Gay CM, Byers L, Cascone T, Tran HT, Lin SH, Carter B, Tam A, Rajaram R, Antonoff M, Ostrin E, Chen H, Blumenschein G, Rice D, Walsh GL, Hofstetter W, Mehran RJ, Wu CC, Vaporciyan A, Zhang B, Araujo H, Moghaddam SJ, Wistuba I, Lee JJ, Heymach JV. Canakinumab Interception Trial and Preclinical Studies Reveal Stage-Dependent Biology in Lung Cancer and Precancers. IASLC 2025 WCLC Annual Meeting.
52. Bose M, Ruoff C, Stewart CA, Bhattacharyya S, Victorian A, Wang R, Duarte A, Ehsan S, Lujan FE, Cardnell R, Gay CM, Byers LA, Karacosta LG. Tracking Ctc Phenotypes in SCLC Liquid Biopsies as a Diagnostic and Therapy Response Assessment Tool. IASLC 2025 WCLC.
53. Stewart A, Ramkumar K, Wang R, Yang Y, Zhang B, Halliday A, Xi Y, Diao L, Wang Q, Duarte A, Li P, Tanimoto A, Serrano A, Vykoukal J, Bose M, Karacosta L, Soto LMS, Hanash S, Wang J, Heymach JV, Byers LA, Gay CM. Surface Targeting Strategies to Overcome Heterogeneity Associated With Treatment Resistance in Small Cell Lung Cancer (SCLC). IASLC 2025 WCLC Annual Meeting.

Book Chapters

1. Halperin D, Wasylishen A, Gay CM. Genetic Drivers of NENs. In: Endocrinology – Neuroendocrine Neoplasia. Springer Nature, 2023.
2. Ross JA, Byers LA, Gay CM. Small Cell Carcinoma of the Lung. In: The MD Anderson Manual of Medical Oncology. 4. McGraw-Hill Education, 2021.

Web Publications

1. Stewart CA, Gay CM. Resistance Contains Multitudes: Increasing Transcriptional Diversity following SCLC Treatment, 2020.